| 臺大學術典藏 |
2018-09-10T15:38:29Z |
Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial
|
Piccart-Gebhart, M. and Holmes, E. and Baselga, J. and De Azambuja, E. and Dueck, A.C. and Viale, G. and Zujewski, J.A. and Goldhirsch, A. and Armour, A. and Pritchard, K.I. and McCullough, A.E. and Dolci, S. and McFadden, E. and Holmes, A.P. and Tonghua, L. and Eidtmann, H. and Dinh, P. and Di Cosimo, S. and Harbeck, N. and Tjulandin, S. and Im, Y.-H. and Huang, C.-S. and D\\'ieras, V. and Hillman, D.W. and Wolff, A.C. and Jackisch, C. and Lang, I. and Untch, M. and Smith, I. and Boyle, F. and Xu, B. and Gomez, H. and Suter, T. and Gelber, R.D. and Perez, E.A.; CHIUN-SHENG HUANG |
